Cellectar Biosciences, Inc. (CLRB) Financials

CLRB Assets vs Liabilities
DateAssetsLiabilities
March 31, 2026 11.1 million 6.4 million
Dec. 31, 2025 15.0 million 5.1 million
Sept. 30, 2025 14.6 million 5.2 million
June 30, 2025 13.7 million 6.2 million

CLRB Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
March 31, 2026 -4.8 million 451869
Dec. 31, 2025 -4.4 million 567788
Sept. 30, 2025 -4.3 million 567788
June 30, 2025 -5.1 million 565391

CLRB Net Income

No data available :(

CLRB Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
March 31, 2026 8.3 million - 1.5 million
Dec. 31, 2025 13.2 million - 309397
Sept. 30, 2025 12.6 million - 431929
June 30, 2025 11.0 million - 453509

CLRB Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
March 31, 2026 4.2 million
Dec. 31, 2025 4.2 million
Sept. 30, 2025 3.2 million
June 30, 2025 1.6 million

CLRB Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
March 31, 2026 3375 3.0 million 2.9 million -
Dec. 31, 2025 5884 3.2 million 2.5 million -
Sept. 30, 2025 1 2.5 million 2.3 million -
June 30, 2025 61286 2.4 million 3.6 million -

CLRB Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
March 31, 2026 - -110018
Dec. 31, 2025 - 49461
Sept. 30, 2025 - 52277
June 30, 2025 - -

CLRB

Price: $2.41

52 week price:
2.20
6.52

Earnings Per Share: -5.38 USD

Exchange: NCM

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 27300

Ebitda: -3.4 million

Market Capitalization: 8.5 million

Links: